Riboflavin 0.1% (VibeX) for the treatment of keratoconus
| Autor: | Stefano Baiocchi, Stefano Caragiuli, Tomaso Caporossi, A. Paradiso, Cosimo Mazzotta, Aldo Caporossi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Keratoconus
medicine.medical_specialty VibeX Visual acuity genetic structures Riboflavin Food and drug administration Corneal ectasia Ophthalmology Ectasia Cornea Accelerated crosslinking medicine Pharmacology (medical) Pharmacology Toxicology and Pharmaceutics (miscellaneous) Crosslinking Irregular astigmatism business.industry Health Policy medicine.disease eye diseases medicine.anatomical_structure VibeX Rapid sense organs medicine.symptom business |
| Zdroj: | Expert Opinion on Orphan Drugs. 1:235-240 |
| ISSN: | 2167-8707 |
| Popis: | Introduction: Keratoconus is an ectatic disease of the cornea characterized by biomechanical instability of stromal collagen leading to reduction of corneal thickness, variation in posterior and anterior corneal curvatures with associated progressive deterioration of visual acuity mainly due to a secondary irregular astigmatism. Corneal collagen crosslinking (CXL) is a new approach to increase the mechanical strength and biochemical stability of the corneal stromal tissue affected from primary or secondary ectasia. A novel pharmacological series of riboflavin formulations from Avedro, Inc. (Waltham, Massachusetts, MA, USA), were recently granted orphan drug designation by the Food and Drug Administration for the treatment of keratoconus and secondary corneal ectasia. Areas covered: This report reviews the basic concepts concerning the role of riboflavin in crosslinking treatment in order to understand the potentiality of the new VibeX™ and VibeX Rapid™ solutions for riboflavin UVA-induced CXL. The treatme... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|